AZN vs NBIX: fair value comparison
AstraZeneca PLC and Neurocrine Biosciences, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our ranking by discount to fair value. NBIX carries the stronger quality grade.
| AZN | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $165.41 | $135.71 |
| 12-month range | $155.62–$209.48 | $123.10–$185.50 |
| Rank by discount to fair value | #1 of 108 Healthcare | #5 of 108 Healthcare |
| Quality grade | C | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AZN fair value analysis · NBIX fair value analysis